Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular ...

Allurion Technologies (ALUR) stock climbed 200% despite a ~7.4M stock and warrants offering announced by the company. Read ...

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

Allurion's flagship offering, the Allurion Program, integrates the Allurion Gastric Balloon, a swallowable device that aids in weight loss without the need for a surgical procedure. The program ...

Allurion cited prior studies demonstrating that its gastric balloon ... issued in its July 2024 offering to $6.00 per share after obtaining shareholder approval. Roth Capital Partners is acting ...

Shares in the NYSE-listed company rose 77% at market open on 24 January 2025, compared to a market close, which occurred shortly after Allurion ... composition. Allurion’s gastric balloon ...

Allurion's flagship offering, the Allurion Program, integrates the Allurion Gastric Balloon, a swallowable device that aids in weight loss without the need for a surgical procedure. The program also ...